Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 6-Week Feasibility Trial of a New Formulation of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD)

NCT00967993 is registered in ClinicalTrials.gov with Keryx Biopharmaceuticals as lead sponsor.

NCT NCT00967993
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00967993 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 6-Week Feasibility Trial of a New Formulation of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD)
Lead sponsor
Keryx Biopharmaceuticals
Phase
Observational
Overall status
Completed
Start date
January 31, 2010
Completion date
May 31, 2010
Enrollment
22 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

end-stage renal disease, hyperphosphatemia, renal failure chronic requiring hemodialysis